Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling

Executive Summary

US FDA wants to work with practitioners to develop suggested prescribing standards, which could then be used to create packaging requirements.

You may also be interested in...



Opioid Treatments Could Get Survival Claim As US FDA Develops Protocol

Commissioner Gottlieb announces several actions in the works to promote development of new treatments for opioid addiction, including guidance on how to establish novel endpoints.

Opioid Packaging Changes Might Deter Abuse – And Generic Competition

US FDA soliciting ideas for opioid packaging and storage technology development; workshop scheduled for December.

FDA's Opioid Programs: After Training, What's The Next Step?

Treatment guidelines may also appear in opioid labeling, and insurers seem to be taking the agency's advice, but will it be enough to satisfy Congress?

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB002154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel